

PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

**Complete If Known**

Application Number	10/505446
--------------------	-----------

Filing Date	March 3, 2003
-------------	---------------

First Named Inventor	Antonio FERRANTE
----------------------	------------------

Art Unit	16E 16FF
----------	----------

Examiner Name	PAUL MARTIN
---------------	-------------

Attorney Docket Number	PAUL M. V. 1 IN 03
------------------------	--------------------

Sheet			of	3
-------	--	--	----	---

P26675CM H:K G

## U. S. PATENT DOCUMENTS

[illegible]

**FOREIGN PATENT DOCUMENTS**

[illegible]

**Examiner  
Signature**

Date  
Considered

2/21/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**



PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

3

**Complete if Known**

Application Number

10/505,446

Filing Date

09/01/2004

First Named Inventor

Antonio FERRANTE

Art Unit

1615 1655

Examiner Name

PAUL MARTIN

Attorney Docket Number

P26675CMH:KG

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate); title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
PCm	1	WINTER C.A. et al, "Carrageenin-induced edema in hind paw of the rat as an assay for antiinflammatory drugs", (1962) Proc. Soc. Exp. Biol. Med., Vol. 111, pages 544-547	
PCm	2	SNOWDEN J.M. and WHITEHOUSE M.W., "Anti-inflammatory activity of emu oils in rats", (1997) Journal of Immunopharmacology, Vol. 5, pages 127-132	
PCm	3	HART P.H. et al, "Terpinen-4-ol, the main component of the essential oil of Melaleuca alternifolia (tea tree oil), suppresses inflammatory mediator production by activated human monocytes", (2000) Inflammation Research, Vol. 49, pages 619-626	
PCm	4	AZUZU I.U. et al, "The antiinflammatory activity of Icacinia trichantha tuber", (1999) Phytomedicine, Vol. 6(4), pages 267-272	
PCm	5	LOPEZ A. et al, "Effect of emu oil on auricular inflammation induced with croton oil in mice", (1999) Am. J. Vet. Res., Vol. 60 (12), pages 1558-1561	
PCm	6	WHITEHOUSE M.W. et al, "Emu oil(s): a source of non-toxic transdermal anti-inflammatory agents in aboriginal medicine", (1997) Journal of Immunopharmacology, Vol. 6, pages 1-8	
PCm	7	FERRANTE A. et al, "Suppression of the immunological responses in mice by treatment with amphotericin B", (1979) Clin. & Exp. Immunol., Vol. 38, pages 70-76	
PCm	8	COSTABILE M. et al, "A novel long chain polyunsaturated fatty acid, $\beta$ -oxa 21:3n-3, inhibits T lymphocyte proliferation, cytokine production, delayed type hypersensitivity, carrageenan-induced paw oedema reaction and selectively targets intracellular signals", (2001) J. Immunol., Vol. 167, pages 3980-3987	
PCm	9	FLETCHER D. et al, "The influence of the timing of bupivacaine infiltration on the time course of inflammation induced by two carrageenin injections seven days apart", (1997) Pain, Vol. 69, pages 303-309	
PCm	10	FERRANTE A. et al, "Inhibition of mitogen induced human lymphocyte responsiveness by polymyxin antibiotics", (1982) Int. Arch. Allerg. & Appl. Immunol., Vol. 69, pages 279-281	

Examiner  
SignatureDate  
Considered

3/21/06

\*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)  
Approved for use through 07/31/2008. OMB 0851-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/505,446
Filing Date	09/01/2004
First Named Inventor	Antonio FERRANTE
Art Unit	1615 1655
Examiner Name	PAUL MARTIN
Attorney Docket Number	P26675CMH:KG

Sheet 3 of 3

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
PCm	11	STAUGAS R.E.M. et al, "Induction of tumour necrosis factor and interleukin -1 by Pseudomonas aeruginosa and exotoxin A-induced suppression of lymphoproliferation, TNF, lymphotoxin, interferon gamma and interleukin -1 in human leukocytes", (1992) Infect. Immun., Vol. 60, pages 3162-3168	
PCm	12	BATES E.J. et al, "Effect of fatty acid structure on neutrophil adhesion, degranulation and damage to endothelial cells", (1995) Atherosclerosis, Vol. 116, pages 247-259	
PCm	13	HUANG Z.H. et al, "Inhibition of stimuli-induced endothelial cell intracellular adhesion molecule -1, E-selectin and vascular cellular adhesion molecule -1 expression by arachidonic acid and its hydroxy- and hydroperoxy-derivatives", (1997) Circulation Research, Vol. 80, pages 149-158	
PCm	14	FERRANTE A. et al, "Neutrophil migration inhibitory properties of polyunsaturated fatty acids: the role of fatty acid structure, metabolism, and possible second messenger systems", (1994) J. Clin. Invest., Vol. 93, pages 1063-1070	
PCm	15	VISIOLI F. and GALLI C., "The effects of minor constituents of olive oil on cardiovascular disease: new findings", (1998) Nutrition Reviews, Vol. 56, pages 142-147	

Examiner Signature	PCm	Date Considered	3/21/06
--------------------	-----	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.